Compare · ACHC vs ILMN
ACHC vs ILMN
Side-by-side comparison of Acadia Healthcare Company Inc. (ACHC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.87B, about 11.6x ACHC ($2.14B).
- Over the past year, ACHC is up 7.8% and ILMN is up 102.8% - ILMN leads by 95.0 points.
- ILMN has been more active in the news (24 items in the past 4 weeks vs 5 for ACHC).
- Both have 25 recent analyst ratings on file.
- Company
- Acadia Healthcare Company Inc.
- Illumina Inc.
- Price
- $23.31+0.30%
- $164.45+0.91%
- Market cap
- $2.14B
- $24.87B
- 1M return
- -9.97%
- +29.84%
- 1Y return
- +7.82%
- +102.77%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 5
- 24
- Recent ratings
- 25
- 25
Acadia Healthcare Company Inc.
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico. The company operates acute inpatient psychiatric facilities, which cares to stabilize patients that are either threat to themselves or others by hourly observation, daily intervention, and monitoring by psychiatrists; and specialty treatment facilities, including residential recovery and eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders. It also provides residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs; and outpatient community-based services, such as community-based programs that are designed to offer therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric, or chemical dependency disorders. In addition, the company provides education and children's, and adult care services. As of March 31, 2021, it operated a network of 228 behavioral healthcare facilities with approximately 10,000 beds. The company was founded in 2005 and is headquartered in Franklin, Tennessee.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ACHC
- SEC Form 8-K filed by Acadia Healthcare Company Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Acadia Healthcare Company Inc.
- SEC Form S-8 filed by Acadia Healthcare Company Inc.
- New insider Duckworth David M. claimed ownership of 750 shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Acadia Healthcare Company Inc.
- Director Fucci Michael was granted 6,331 shares, increasing direct ownership by 29% to 28,152 units (SEC Form 4)
- Director Waud Reeve B was granted 15,907 shares, increasing direct ownership by 27% to 75,859 units (SEC Form 4)
- Director Bernhard Jason was granted 11,455 shares, increasing direct ownership by 34% to 45,359 units (SEC Form 4)
- Director Harris Patrice A was granted 6,331 shares, increasing direct ownership by 55% to 17,914 units (SEC Form 4)
- Director Kelly Ralph David was granted 6,331 shares, increasing direct ownership by 32% to 26,358 units (SEC Form 4)
Latest ILMN
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)
- Director Siegel Susan E was granted 2,072 shares, increasing direct ownership by 14% to 16,535 units (SEC Form 4)